EC Offers Cash Prize for Vaccine Stability - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EC Offers Cash Prize for Vaccine Stability


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Commission (EC) is offering a EUR 2-million ($2.64 million) inducement prize to encourage innovation in the area of cold-chain logistics and vaccine stability. According to the EC, the need to keep vaccines stable at any ambient temperature is a huge barrier to using vaccines in developing countries or tropical climates. The prize was announced at the third Innovation in Healthcare conference in Brussels by the Research, Innovation and Science Commissioner Máire Geoghegan-Quinn.

In a statement, Geoghegan-Quinn said: "Many people in tropical and developing countries cannot benefit from life-saving vaccines as these vaccines are damaged before they can reach them. The goal of this prize is to galvanize scientists into producing innovations which can solve this global health problem."

Vaccine delivery from manufacturers to recipients can take 18 months. During this time, most vaccines must be kept at a constant, suitable temperature. Often, this requires an unbroken cold chain, but such a system can be difficult to implement in developing countries, which means vaccines are often rendered ineffective before they reach their recipients. In a statement, the EC quotes the World Health Organization’s claim that half of all supplied vaccine doses are wasted — mainly by an inadequate cold-chain.

The winner will be announced in 2013, and must convince a panel of judges that vaccines can be safely transported and stored in field conditions such that they retain their full potency, effectiveness and safety. In addition, the solution should be able to be implemented at reasonable cost.

In Europe, funding worth EUR 400 million ($529 million) has already been awarded through Research Framework Programs 6 and 7 for projects relating to vaccine research. However, cold-chain technology has never been a focus of either of the framework programs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here